Companies › Sling Therapeutics
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Metabolic and endocrine, Ophthalmology; next expected readout Jun 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| linsitinib Insulin-like growth factor I receptor inhibitor; Insulin receptor inhibitor | IGF1R, INSR | Phase 3 | Thyroid Eye Disease, TED; Thyroid Eye Disease | Jun 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06112340 | linsitinib | Phase 2 | Thyroid Eye Disease | Metabolic and endocrine | Jun 2026 |
| NCT07753603 | linsitinib | Phase 3 | Thyroid Eye Disease, TED | Ophthalmology | Jun 2028 |
Viridian Therapeutics Nacuity Pharmaceuticals ReGenTree Xintian Pharmaceutical Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.